Ambrx Biopharma AMAM 深 滬
等待開盤 09-03 09:30:00 美东时间
28.00
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 28.00
- 總市值 17.36亿
- 52周最高 28.15
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 6.55
- 委 比 0.00%
- 總股本 6201.00万
- 歷史最高 28.15
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.38
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 28, 2025 /PRNewswire/ -- Federal budget cuts have put pressure on cancer research efforts in th...
08-28 22:44
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- USA News Group News Commentary – Federal budget cuts have put pressure...
08-15 00:22
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary – The average age of cancer patients is getting younger, as experts ...
07-30 03:46
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs c...
07-08 22:25
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulle...
06-30 23:02
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global ...
06-26 23:44
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to c...
06-25 00:52
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- Equity Insider News Commentary – The 2025 ASCO Annual Meeting has wrap...
06-12 22:00
Oncolytics names Jared Kelly as CEO
Oncolytics Biotech (NASDAQ:ONCY) has announced the appointment of Jared Kelly as CEO and a member of its Board of Directors. Most recently, he played a central role in orchestrating the sale of Ambrx ...
06-11 19:46
Oncolytics Names Jared Kelly CEO, Wayne Pisano Steps Down After Guiding Immunotherapy Progress
Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Jared Kelly as Chief Executive Officer and a
06-11 19:07
